Regeneron/Bayers VEGF Trap eye shows efficacy in AMD

Data presented at the Retina Society meeting show Bayer/Regeneron’s VEGF Trap-Eye can improve visual acuity and biologic parameters related to the formation of new blood vessels in the treatment of age-related macular degeneration (AMD).

Bayer/Onyx initiate new Phase III trial for Nexavar in liver cancer

Bayer and Onyx have announced the initiation of a Phase III study of Nexavar (sorafenib) as an adjuvant therapy for patients with hepatocellular carcinoma

Sunitinib and Sorafenib cause Erythrocytosis, Indicative of class effect?

Researchers report that the development of reversible erythrocytosis is a common side effect following the use of sorafenib and sunitiniband may be a class specific adverse effect with all kinase inhibitors

VEGF-Trap effective in Phase II AMD trial

Phase II data released by Bayer and Regeneron show VEGF Trap-Eye is effective in patients with wet age-related macular degeneration (AMD).

Sorafenib in Neurofibromatosis/Neurofibromas

The NCI are initiating a phase I trial of Sorafenib in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery

NICE recommends against Avastin, Nexavar, Sutent and Torisel for Kidney Cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary ruling stating that Avastin, Nexavar, Sutent and Torisel  are not  effective enough to warrant their high cost and shouldn’t be prescribed to new patients in Britain.

Nycomed sell kinase program to Bayer Schering

Nycomed have completed the sale of a preclinical kinase program comprising two potential drug candidates and an extensive back-up program to Bayer Schering. This deal follows Nycomed’s strategic decision not to further invest in oncology R&D activities.

Sorafenib and Bevacizumab combination therapy increases antitumor activity

Combining Sorafenib and Bevacizumab has been shown to increase antitumur activity in patients with advanced solid tumors, especially those with ovarian cancer.

Nexavar approved for hepatocellular carcinoma in China

Bayer and Onyx have announced that Nexavar has been approved for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer in China

Sorafenib shows efficacy in Phase III hepatocellular carcinoma trial

Sorafenib has been shown to be effective in patients with advanced hepatocellular carcinoma. The median survival and time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.